This company has been acquired
Chembio Diagnostics Management
Management criteria checks 2/4
Key information
Richard Eberly
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 28.6% |
| CEO tenure | 3.1yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2.2yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
Chembio gets $3.2M contract from CDC to develop rapid test for syphilis
Sep 06Chembio stock rises 13% amid plans to develop rapid test for monkeypox
Aug 16Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt In A Risky Way?
Nov 30
Analysts' Revenue Estimates For Chembio Diagnostics, Inc. (NASDAQ:CEMI) Are Surging Higher
Aug 08Does Chembio Diagnostics (NASDAQ:CEMI) Have A Healthy Balance Sheet?
Jul 22Chembio Diagnostics EPS beats by $0.10, beats on revenue
May 06Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt Sensibly?
Apr 07Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Shareholder Ownership Skewed Towards Insiders?
Jan 16Chembio stock gains after COVID-19 tests nab European Union nod
Jan 14Is Chembio Diagnostics (NASDAQ:CEMI) Weighed On By Its Debt Load?
Dec 12
Chembio slumps 13% on delay of U.S. nod for coronavirus antibody test
Dec 04Chembio nabs BARDA contract for rapid respiratory antigen panel test
Dec 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | US$2m | US$460k | -US$23m |
| Sep 30 2022 | n/a | n/a | -US$36m |
| Jun 30 2022 | n/a | n/a | -US$36m |
| Mar 31 2022 | n/a | n/a | -US$38m |
| Dec 31 2021 | US$2m | US$477k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$26m |
| Mar 31 2021 | n/a | n/a | -US$25m |
| Dec 31 2020 | US$1m | US$315k | -US$26m |
Compensation vs Market: Richard's total compensation ($USD1.61M) is above average for companies of similar size in the US market ($USD767.83K).
Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.
CEO
Richard Eberly (61 yo)
3.1yrs
Tenure
US$1,610,406
Compensation
Mr. Richard L. Eberly serves as the President and Chief Executive Officer at Chembio Diagnostics, Inc. since March 16, 2020 and has been its Director since May 02, 2020. He joined Chembio in March, 2020. H...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.1yrs | US$1.61m | 1.03% $ 171.6k | |
| Executive VP | 1.3yrs | US$1.05m | 0.15% $ 24.4k | |
| Executive VP and Chief Scientific & Technology Officer | 19.3yrs | US$765.96k | 0.50% $ 84.2k | |
| Executive VP & COO | 3yrs | no data | 0.021% $ 3.6k | |
| Vice President of Human Resources | 1.4yrs | no data | no data | |
| Senior Vice President of Global Commercial Operations | 1.3yrs | no data | 0.021% $ 3.6k |
2.2yrs
Average Tenure
59yo
Average Age
Experienced Management: CEMI's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.9yrs | US$1.61m | 1.03% $ 171.6k | |
| Independent Director | less than a year | US$143.43k | no data | |
| Independent Director | 4.9yrs | US$100.31k | 0.15% $ 24.6k | |
| Independent Chairperson | 15.9yrs | US$123.89k | 0.31% $ 52.0k | |
| Independent Director | 2.3yrs | US$91.56k | 0.040% $ 6.7k | |
| Independent Director | 2.1yrs | US$94.06k | 0.031% $ 5.2k |
2.6yrs
Average Tenure
64yo
Average Age
Experienced Board: CEMI's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/27 02:20 |
| End of Day Share Price | 2023/04/27 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chembio Diagnostics, Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Raymond Myers | Benchmark Company |
| Mark Massaro | Canaccord Genuity |